ArticleCancer immunology, immunotherapy : CII2011
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
Article in Cancer immunology, immunotherapy : CII, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.Cancer immunology research · 2014Trial
- Article
- Advances and challenges in anti-cancer vaccines for multiple myeloma.Frontiers in immunology · 2024Review
- Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.Pharmaceutics · 2022Review
- Novel immunotherapies in multiple myeloma.International journal of hematology · 2022Review
- The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.International journal of molecular sciences · 2022Review
- Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients.Oncoimmunology · 2022Article
- Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Oncology reports · 2017Article
- Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.Iranian journal of cancer prevention · 2015Review
- Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Review
- Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic.Chonnam medical journal · 2015Review
- Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen.Cancer immunology, immunotherapy : CII · 2015Article
- Review
- Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?Current hematologic malignancy reports · 2013Review
- Reassessing target antigens for adoptive T-cell therapy.Nature biotechnology · 2013Review
- Immunotherapy strategies for multiple myeloma: the present and the future.Immunotherapy · 2013Review
- MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients.Leukemia · 2013Article
- Combined analysis of serum alpha-fetoprotein and MAGE-A3-specific cytotoxic T lymphocytes in peripheral blood for diagnosis of hepatocellular carcinoma.Disease markers · 2013Article
- Database of T cell-defined human tumor antigens: the 2013 update.Cancer immunity · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Multiple myeloma is incurable with standard therapies but is susceptible to a T-cell-mediated graft versus myeloma effect after allogeneic stem cell transplantation. We sought to identify myeloma-specific antigens that might be used for T-cell immunotherapy of myeloma. MAGE-C1 (CT-7) is a cancer-testis antigen that is expressed by tumor cells in >70% of myeloma patients and elicits a humoral response in up to 93% of patients with CT-7(+) myeloma. No CD8(+) T-cell epitopes have been described for CT-7, so we used a combination of reverse immunology and immunization of HLA-A2 transgenic mice with a novel cell-based vaccine to identify three immunogenic epitopes of CT-7 that are recognized by human CD8(+) T-cells. CT-7-specific T-cells recognizing two of these peptides are able to recognize myeloma cells as well as CT-7 gene-transduced tumor cells, demonstrating that these epitopes are naturally processed and presented by tumor cells. This is the first report of the identification of immunogenic CD8(+) T-cell epitopes of MAGE-C1 (CT-7), which is the most commonly expressed cancer-testis antigen found in myeloma, and these epitopes may be promising candidate targets for vaccination or T-cell therapy of myeloma or other CT-7(+) malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.